Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 proof-of-activity study of oral posaconazole in asymptomatic chronic Chagas disease
2013-000161-36Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of posaconazole and benznidazole in American trypanosomiasis (CD) (4 arms), sponsored by Merck & Co. Primary endpoint: Successful response for posaconazole versus placebo. Started Jun 2013; status: completed.
02
Drugs
posaconazolebenznidazole
03
Conditions
American trypanosomiasis (CD)
Beyond the preview
Go deeper on 2013-000161-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000161-36.